Physician profile
Vanitha Yadalla
NPI 1093702961
$6,563.20
in general payments reported to CMS, 2019-2025
35 companies · $983 in 2025
The $983 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,021 · 2020: $331 · 2021: $1,636 · 2022: $512 · 2023: $588 · 2024: $1,493 · 2025: $983.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,059 · Education: $5.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,058.72 |
| Education | $5.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,567.02 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Biohaven Pharmaceuticals, INC. | $1,210.22 | 2021 | |
| Pfizer INC. | $775.45 | 2019-2025 | |
| Abbvie INC. | $585.30 | 2021-2025 | Vraylar |
| Novo Nordisk INC | $353.23 | 2019-2025 | Ozempic, Rybelsus |
| Astellas Pharma US INC | $269.30 | 2019-2023 | Veozah |
| Glaxosmithkline, LLC. | $236.99 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Exact Sciences Corporation | $212.74 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $139.71 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.52 | 2019-2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $121.81 | 2024 | Eliquis |
| Amgen INC. | $94.10 | 2022-2023 | Otezla, Repatha |
| Hologic Sales and Service, LLC | $90.90 | 2024 | Coolseal Generator |
| Bayer Healthcare Pharmaceuticals INC. | $78.82 | 2022-2025 | |
| Ibsa Pharma INC. | $70.28 | 2019-2023 | Tirosint, Licart |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $65.00 | 2024-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $52.31 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $43.32 | 2019-2023 | Belsomra, Januvia |
| Amarin Pharma, INC. | $42.45 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.91 | 2019-2023 | Xifaxan |
| Davol INC. | $40.00 | 2024 | Phasix Mesh |
| Takeda Pharmaceuticals U.S.A., INC. | $39.14 | 2019 | |
| Abbott Laboratories | $33.00 | 2024 | Freestyle Libre 3 |
| Bausch Health US, LLC | $31.97 | 2023 | Aplenzin |
| Globus Medical, INC. | $30.59 | 2025 | Senza |
| Allergan, INC. | $27.68 | 2019 | |
| Currax Pharmaceuticals LLC | $27.04 | 2021-2024 | Contrave |
| Arbor Pharmaceuticals, INC. | $26.33 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $25.28 | 2022 | |
| Koya Medical, INC. | $18.93 | 2025 | Koya Medical, Dayspring |
| Sumitomo Pharma America, INC. | $17.61 | 2025 | Gemtesa |
| Eisai INC. | $15.95 | 2022 | |
| Supernus Pharmaceuticals, INC. | $15.91 | 2019 | |
| Horizon Therapeutics Plc | $13.94 | 2022 | |
| Acella Pharmaceuticals, LLC | $13.45 | 2024 | NP Thyroid 60 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vanitha Yadalla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.